a)De Clercq, E.
Antiviral drug strategies; Wiley-VCH, Vol. 50,
2011, pp. 1-406.
[
http://dx.doi.org/10.1002/9783527635955]
b)Hishitsuka, H.; Shimma, N. Modified Nucleosides. In:
Biochemistry, Biotechnology and Medicine; Piet Herdewijn. Ed.; Wiley,
2008; p. 587-600.
d)Thottassery, J.V.; Westbrook, L.; Someya, H.; Parker, W. B. c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-Darabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
Mol. Cancer Therapeut, 2006,
5(2), 400-410.
[
http://dx.doi.org/10.1158/1535-7163.MCT-05-0409] [PMID:
16505115]
c)Miura, S.; Izuta, S. DNA polymerases as targets of anticancer nucleosides.
Curr. Drug Targets, 2004,
5(2), 191-195.
[
http://dx.doi.org/10.2174/1389450043490578] [PMID:
15011952]
d)Klopfer, A. Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway.
Oncogene, 2004,
23, 9408-9418.
[
http://dx.doi.org/10.1038/sj.onc.1207975]
e)F. De, Clercq E. The history of antiretrovirals: key discoveries over the past 25 years.
Rev. Med. Virol., 2009,
19, 287-299.
[
http://dx.doi.org/10.1002/rmv.624] [PMID:
19714702]
f)De Clercq, E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
Biochem. Pharmacol., 2007,
73, 911-922.
[
http://dx.doi.org/10.1016/j.bcp.2006.09.014] [PMID:
17045247]
g)Cihlar, T.; LaFlamme, G.; Fisher, R.; Carey, A.C.; Vela, J.E.; Mackman, R.; Ray, A.S. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
Antimicrob. Agents Chemother., 2009,
53(1), 150-156.
[
http://dx.doi.org/10.1128/AAC.01183-08] [PMID:
19001108]
h)Choo, H.; Beadle, J.R.; Kern, E.R.; Prichard, M.N.; Keith, K.A.; Hartlina, C.B.; Trahan, J.; Aldern, K.A.; Korba, B.E.; Hostetler, K.Y. Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters.
Antimicrob. Agents Chemother., 2007,
51, 611-615.
[
http://dx.doi.org/10.1128/AAC.00444-06] [PMID:
17130297]
i)Krcmerova, M.; Holy, A.; Piskala, A.; Masojidkova, M.;
Andrei, G.; Naesens, L.; Neyts, J.; Balzarini, J.; De Clercq,
E.; Snoeck, R. Antiviral activity of triazine analogues of 1-
(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir)
and related compounds.
J. Med.Chem., 2007,
50(5), 1069-1077.
[
http://dx.doi.org/10.1021/jm061281+] [PMID:
17298047]
j)Lebeau,
I.; Andrei, G.; Krecmerova, M.; De Clercq, E.; Holy, A.;
Snoeck, R. Inhibitory activities of three classes of acyclic
nucleoside phosphonates against murine polyomavirus and
primate simian virus 40 strains.
Antimicrob. Agent Chemother., 2007,
51(6), 2268-2273.
[
http://dx.doi.org/10.1128/AAC.01422-06] [PMID:
17420214]
k)Vanek,V.; Budesinsky, M.; Rinnova, M.; Rosemberg, I.
Prolinol-based nucleoside phosphonic acids: new isosteric
conformationally flexible nucleotide analogues.
Tetrahedron, 2009,
65(4), 862-876.
[
http://dx.doi.org/10.1016/j.tet.2008.11.035]
l)Kumamoto,
H.; Topalis, D.; Broggi, J.; Pradere, U.; Roi, V.; Berteina-
Raboin, S.; Nolan, S. P.; Deville,-Bonne, D.; Andrei, G.;
Snoeck, R.;Garin, D.; Grance, G. M.; Agrofoglio, L. A.
Preparation of acyclo nucleoside phosphonate analogues
based on cross-metathesis.
Tetrahedron, 2008,
64(16), 3517-3526.
[
http://dx.doi.org/10.1016/j.tet.2008.01.140]
m)Vrbkova, S.;
Dracinsky, M.; Holy, A. Synthesis of phosphonomethoxyethyl
or 1,3 bis(phosphonomethoxy)propan-2-yllipophilic esters of acyclic nucleoside phosphonates.
Tetrahedron, 2007,
63(46), 11391-11398.
[
http://dx.doi.org/10.1016/j.tet.2007.08.081]